32.48  0.01 (0.03%)		03-21 16:00
Open: 32.49 High: 32.5 Volume: 8,354,629		Pre. Close: 32.47 Low: 32.48 Market Cap: 3,728(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Mon, 11 Mar 2024
Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain - Yahoo Finance

Mon, 12 Feb 2024
Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion - Investopedia

Mon, 12 Feb 2024
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics - Business Wire

Mon, 12 Feb 2024
CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis - PR Newswire

Fri, 15 Dec 2023
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis - PR Newswire

Tue, 14 Nov 2023
East Bay company's 'greatest biotech comeback' drives toward drug approval in rare liver disease - The Business Journals

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date